29 January 2013
Class 3 medicines recall
Action within 5 days
Marlborough Pharmaceuticals Ltd
Gygel Contraceptive Jelly
||31 March 2012
Marlborough Pharmaceuticals Ltd is recalling the above batch as a precaution because the results of assays carried out on one of the preservatives during routine stability studies did not comply with the required specification. Preservative efficacy tests carried out on this batch at the same time point complied with the Ph. Eur. specification so this finding is not expected to pose a risk to patient safety.
Remaining stocks of the affected batches should be quarantined and returned to the original supplier for credit. For enquiries relating to stock returns please contact UDG Credit Claims at email@example.com
For medical information enquiries please contact 01748 828 789 (24 hour).
Recipients of this drug alert should bring it to the attention of relevant contacts by copy of this letter. Primary care trusts are asked to forward this to relevant clinics and to general practitioners and community pharmacists for information.
Further recipients by cascade):
Regional contacts for NHS Trusts and provider units
Chief pharmacists: England, Scotland, Wales, Northern Ireland
Prison health policy unit (DH)
Chief pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Healthcare Commission for distribution to independent health care establishments
Primary care trusts (England)
Published 17 December 2014